Vigabatrin Powder, For Solution
Product Images NDC 59651-366

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Vigabatrin (NDC 59651-366). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Vigabatrin Fig1)

A line graph titled 'Percent Reduction from Baseline in Seizure Frequency' showing the percentage reduction in seizure frequency on the y-axis and the percentage of patients on the x-axis for different treatment groups. Four curves represent placebo, 1g/day Vigabatrin, 3g/day Vigabatrin, and 6g/day Vigabatrin, illustrating varying degrees of seizure frequency reduction with increasing doses. The graph also indicates directions for improvement and worsening relative to baseline seizure frequency.*

FDA Label Image

Figure F (Vigabatrin Fig10)

An instructional illustration showing a hand holding a syringe over a clear glass beaker, demonstrating preparation or measurement of a liquid. No specific drug details are visible within the image itself.*

FDA Label Image

Figure G (Vigabatrin Fig11)

Figure G is a black-and-white illustration showing a spoon placed inside a small glass jar or container. A liquid is being poured onto the spoon from above, demonstrating a pouring or measuring action, likely related to oral medication preparation.*

FDA Label Image

Figure H (Vigabatrin Fig12)

Illustration showing a hand inserting a measuring syringe into a transparent glass container. The syringe is being filled or emptied inside the container, which is likely used for preparing or measuring liquid medication solutions.*

FDA Label Image

Figure I (Vigabatrin Fig13)

Illustration showing a hand holding a syringe filled with a liquid, demonstrating measurement up to 10 ml. The syringe is marked with graduated volume indicators and a plunger used for oral dosing, likely related to the preparation or administration of Vigabatrin powder for solution.*

FDA Label Image

Figure J (Vigabatrin Fig14)

An instructional illustration labeled 'Figure J' showing an adult administering oral medication to a young child using an oral syringe placed into the child's mouth.*

FDA Label Image

Package Label-principal Display Panel (500 mg (Packet))

Vigabatrin for Oral Solution, USP 500 mg powder for solution in 1 packet. The label indicates it is Rx only, with instructions to pharmacists to dispense the Medication Guide. The product is labeled with NDC 59651-366-07 and distributed by Aurobindo Pharma Limited.*

FDA Label Image

Package Label-principal Display Panel (500 mg (50 Packets Carton))

The packaging label for Vigabatrin for Oral Solution, USP shows a 500 mg strength powder for solution dosage form. The label indicates the product is intended for oral use and contains 50 packets per package. It is distributed by Aurobindo Pharma USA, Inc. and manufactured by Aurobindo Pharma Limited. Directions for use specify mixing each packet with 10 mL of water. The label includes NDC 59651-366-50.*

FDA Label Image

Figure 2 (Vigabatrin Fig2)

A line graph titled 'Percent Reduction from Baseline in Seizure Frequency' displaying cumulative percentage of patients against percent reduction in seizure frequency. Two lines compare a placebo group and a 3g/day Vigabatrin (VGB) treatment group. The vertical axis ranges from -100% to 100% indicating worsening to improvement, and the horizontal axis shows patient percentage from 100% to 0%.*

FDA Label Image

Figure3 (Vigabatrin Fig3)

Packaging for Vigabatrin 500 mg oral solution powder includes a small printed label with the product name, strength, and formulation. The label shows Vigabatrin for Oral Solution, USP 500 mg, from Aurobindo Pharma Limited. The image also features a syringe, scissors, and two small glass containers, one with a spoon inside, suggesting preparation or administration tools for the oral solution powder.*

FDA Label Image

Oral Syringe Detail (Vigabatrin Fig4)

An instructional diagram showing an oral syringe labeled with parts including the tip, dosage indicators, barrel, bottom of white plunger, and plunger. This image illustrates how to identify the components of an oral syringe used for dosing.*

FDA Label Image

Figure5 (Vigabatrin Fig5)

Illustration showing a hand dispensing a sachet labeled Vigabatrin powder for solution into a glass container, demonstrating the preparation of oral medication.*

FDA Label Image

Figure B (Vigabatrin Fig6)

Illustration showing two small glass containers, one empty and the other partially filled with liquid. The image is labeled as Figure B, likely depicting a step or comparison relevant to the use or preparation of a pharmaceutical solution.*

FDA Label Image

Figure C (Vigabatrin Fig7)

An illustration showing a syringe being inserted into a glass container with a clear liquid, likely demonstrating preparation or measurement steps for an oral solution dosage form.*

FDA Label Image

Figure D (Vigabatrin Fig8)

An instructional illustration showing a hand holding an oral dosing syringe filled with liquid. The syringe is marked in milliliters up to 10 mL, demonstrating preparation or measurement of an oral solution dose.*

FDA Label Image

Figure E (Vigabatrin Fig9)

An instructional figure labeled 'Figure E' showing a hand holding a syringe or measuring device next to a bottle or vial, demonstrating alignment with the 10 mL measurement line indicated by an arrow and label.*

FDA Label Image

Chemical Structure (Vigabatrin Str)

Chemical structure diagram of the active ingredient Vigabatrin showing its molecular framework, including amine, vinyl, and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.